Overview

A Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab in Participants With Selected Hyaluronan High Solid Tumors

Status:
Completed

Trial end date:
2019-03-26

Target enrollment:

Participant gender:

Summary

This is a Phase 1b study evaluating a combination of PEGPH20 and pembrolizumab in hyaluronan-high (HA-high) participants with relapsed/refractory non-small cell lung cancer (NSCLC) and HA-high participants with relapsed/refractory gastric adenocarcinoma (GAC).

Phase:

Phase 1

Details

Lead Sponsor:

Halozyme Therapeutics

Treatments:

Pembrolizumab